Your fact-checks will appear here
Research on Alzheimer’s disease, frontotemporal dementia, vascular cognitive impairment and rarer syndromes.
Elon Musk is not marketing or clinically producing a “cognitive decline medicine” in the conventional pharmaceutical sense; his high-profile activity in the field centers on Neuralink, a brain‑compute...
A broad ecosystem of federal agencies, academic medical centers, advocacy groups, and pharmaceutical companies is actively running and sponsoring dementia trials ranging from early-phase biology and b...
Medically accepted causes of Alzheimer’s center on neurodegenerative changes — notably extracellular amyloid plaques and intracellular tau neurofibrillary tangles — and treatments today can only slow ...
No — there is no evidence that Bill Gates and Dr. Sanjay Gupta discovered a cure for memory loss or Alzheimer’s disease: mainstream reporting at the time shows Gates pledged research funding and Gupta...
Bee venom (BV) and its purified components—melittin, phospholipase A2 (bvPLA2), apamin—show anti-inflammatory, antioxidant and neuroprotective effects in laboratory models of neurodegeneration and neu...
The viral “Ben Carson honey recipe” that promises rapid reversal of memory loss is a promotional scam: major fact‑checkers found the endorsements and news articles tying Carson to miracle dementia cur...
The Government Accountability Office (GAO) has concluded that stronger, clearer oversight is needed for memory and Alzheimer’s dietary supplements and has urged federal agencies to take additional act...
There is no verified cure for Alzheimer’s disease today; major research organizations and recent reviews state treatments can slow or modestly alter disease progression but do not reverse it . Publici...
Dr. Sanjay Gupta approaches mental health as a broad public-health and brain‑health communicator, emphasizing prevention, lifestyle and access to care through media, moderation of expert forums and ed...
The FDA has accepted a supplemental New Drug Application (sNDA) for AXS‑05 to treat agitation in Alzheimer’s disease and granted Priority Review with a PDUFA action date of April 30, 2026, moving a co...